BlackRock Inc. Acquires New Stake in Edwards Lifesciences Corporation $EW

Key Points

• BlackRock acquired 58.8 million shares of Edwards Lifesciences worth approximately $5.32 billion, giving it a 10.21% stake. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 EPS on $1.74 billion in revenue, with revenue rising 13.6% year over year. The company issued third-quarter EPS guidance of $0.71–$0.77.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $100.27, versus a reported share price of $91.13.

BlackRock Inc. bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 58,789,433 shares of the medical research company's stock, valued at approximately $5,318,092,000. BlackRock Inc. owned approximately 10.21% of Edwards Lifesciences at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.4%

Shares of NYSE EW opened at $91.13 on Wednesday. The stock has a market capitalization of $52.47 billion, a price-to-earnings ratio of 52.37, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The firm has a 50-day moving average price of $88.90 and a 200 day moving average price of $84.49. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm's quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company's stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Evercore restated an "outperform" rating and set a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. UBS Group assumed coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a "buy" rating and a $110.00 target price on the stock. TD Cowen reiterated a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a "hold" rating in a report on Friday, April 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source